Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide.
Thalidomide has shown its efficacy in the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT) patients. We hypothetize that, owing to its anti-inflammatory/antiangiogenic/vascular growth maturation properties, thalidomide should be useful in the prophylaxis and therapy of HHT patients presenting with initial lung involvement.